Cefdinir

Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes. It is grouped under the following drug class(es): Beta-lactams and Cephalosporins. Its therapeutic use is listed as anti-infectives, antibacterials and antibiotics. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Omnicef and Cefzon. Its PubChem CID is 6915944.